Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sara Cacciapuoti

Showing results (21-30 of 84) with videos related to

Pageof 9
Sort By:
Clinical, Cosmetic and Investigational Dermatology|November 29, 2023
Herpes Zoster and COVID-19 Vaccination: A Narrative ReviewLuca Potestio, Matteo Megna, Alessia Villani, et al.
Journal of Clinical Medicine|May 13, 2023
Long-Term Efficacy and Safety of Risankizumab for Moderate to Severe Psoriasis: A 2-Year Real-Life Retrospective StudyMatteo Megna, Angelo Ruggiero, Teresa Battista, et al.
Journal of Clinical Medicine|April 3, 2021
Ocular Manifestations in Psoriasis Screening (OcMaPS) Questionnaire: A Useful Tool to Reveal Misdiagnosed Ocular Involvement in PsoriasisAngelo Ruggiero, Gabriella Fabbrocini, Sara Cacciapuoti, et al.
Acta Dermatovenerologica Croatica : ADC|May 14, 2015
Efficacy of narrowband UVB phototherapy in erythema dyschromicum perstans treatment: case reportsGabriella Fabbrocini, Sara Cacciapuoti, Rosanna Izzo, et al.
Clinical, Cosmetic and Investigational Dermatology|March 1, 2024
L-Lysine as an Alternative Treatment for Pityriasis Rosea (PR) [Response to Letter]Luca Potestio, Fabrizio Martora, Sara Cacciapuoti, et al.
Clinical and Experimental Dermatology|October 14, 2024
Impact of tildrakizumab on the quality of life of patients with moderate-to-severe psoriasis: a 36-week prospective monocentric real-life observational studySara Cacciapuoti, Teresa Battista, Luca Potestio, et al.
Clinical, Cosmetic and Investigational Dermatology|January 15, 2024
Pityriasis Rosea and Pityriasis Rosea-Like Eruption Following COVID-19 Vaccination: A Narrative ReviewLuca Potestio, Fabrizio Martora, Sara Cacciapuoti, et al.
Clinical, Cosmetic and Investigational Dermatology|March 6, 2023
Tildrakizumab for the Treatment of Moderate-to-Severe Psoriasis: Results from 52 Weeks Real-Life Retrospective StudyAngelo Ruggiero, Gabriella Fabbrocicni, Sara Cacciapuoti, et al.
Giornale Italiano Di Dermatologia E Venereologia : Organo Ufficiale, Societa Italiana Di Dermatologia E Sifilografia|October 19, 2020
Coronavirus disease and dermatology: current and future challengesMaria C Annunziata, Matteo Megna, Maddalena Napolitano, et al.
Expert Opinion on Drug Safety|February 15, 2020
Safety concerns with current treatments for psoriasis in the elderlyRoberta Di Caprio, Giuseppina Caiazzo, Sara Cacciapuoti, et al.
Pageof 9

Showing results (21-30 of 84) with videos related to

Sort By:
Pageof 9
Clinical, Cosmetic and Investigational Dermatology|November 29, 2023
Herpes Zoster and COVID-19 Vaccination: A Narrative ReviewLuca Potestio, Matteo Megna, Alessia Villani, et al.
Journal of Clinical Medicine|May 13, 2023
Long-Term Efficacy and Safety of Risankizumab for Moderate to Severe Psoriasis: A 2-Year Real-Life Retrospective StudyMatteo Megna, Angelo Ruggiero, Teresa Battista, et al.
Journal of Clinical Medicine|April 3, 2021
Ocular Manifestations in Psoriasis Screening (OcMaPS) Questionnaire: A Useful Tool to Reveal Misdiagnosed Ocular Involvement in PsoriasisAngelo Ruggiero, Gabriella Fabbrocini, Sara Cacciapuoti, et al.
Acta Dermatovenerologica Croatica : ADC|May 14, 2015
Efficacy of narrowband UVB phototherapy in erythema dyschromicum perstans treatment: case reportsGabriella Fabbrocini, Sara Cacciapuoti, Rosanna Izzo, et al.
Clinical, Cosmetic and Investigational Dermatology|March 1, 2024
L-Lysine as an Alternative Treatment for Pityriasis Rosea (PR) [Response to Letter]Luca Potestio, Fabrizio Martora, Sara Cacciapuoti, et al.
Clinical and Experimental Dermatology|October 14, 2024
Impact of tildrakizumab on the quality of life of patients with moderate-to-severe psoriasis: a 36-week prospective monocentric real-life observational studySara Cacciapuoti, Teresa Battista, Luca Potestio, et al.
Clinical, Cosmetic and Investigational Dermatology|January 15, 2024
Pityriasis Rosea and Pityriasis Rosea-Like Eruption Following COVID-19 Vaccination: A Narrative ReviewLuca Potestio, Fabrizio Martora, Sara Cacciapuoti, et al.
Clinical, Cosmetic and Investigational Dermatology|March 6, 2023
Tildrakizumab for the Treatment of Moderate-to-Severe Psoriasis: Results from 52 Weeks Real-Life Retrospective StudyAngelo Ruggiero, Gabriella Fabbrocicni, Sara Cacciapuoti, et al.
Giornale Italiano Di Dermatologia E Venereologia : Organo Ufficiale, Societa Italiana Di Dermatologia E Sifilografia|October 19, 2020
Coronavirus disease and dermatology: current and future challengesMaria C Annunziata, Matteo Megna, Maddalena Napolitano, et al.
Expert Opinion on Drug Safety|February 15, 2020
Safety concerns with current treatments for psoriasis in the elderlyRoberta Di Caprio, Giuseppina Caiazzo, Sara Cacciapuoti, et al.
Pageof 9